Zura Bio (ZURA) Stock Price, News & Analysis

Company Overview

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Key Stats

• Today's Range: $1.32 to $1.45
• 50-Day Range: $1.03 to $1.49
• 52-Week Range: $0.97 to $6.35
• Volume: 163,088 shs
• Average Volume: 386,360 shs
• Market Capitalization: $93.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.67
• Consensus Rating: Buy

Zura Bio Stock Analysis - MarketRank™

Zura Bio scored higher than 62% of companies evaluated by MarketBeat, and ranked 720th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Zura Bio has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Zura Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Zura Bio are expected to decrease in the coming year, from ($0.65) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zura Bio is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zura Bio is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zura Bio has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.59% of the float of Zura Bio has been sold short.

Short Interest Ratio / Days to Cover

Zura Bio has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Zura Bio has recently decreased by 51.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zura Bio does not currently pay a dividend.

Dividend Growth

Zura Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.59% of the float of Zura Bio has been sold short.

Short Interest Ratio / Days to Cover

Zura Bio has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Zura Bio has recently decreased by 51.77%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.02

News Sentiment

Zura Bio has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Zura Bio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zura Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ZURA Stock Analysis - Frequently Asked Questions

How have ZURA shares performed this year?

Zura Bio's stock was trading at $2.50 on January 1st, 2025. Since then, ZURA shares have decreased by 45.2% and is now trading at $1.37.
View the best growth stocks for 2025 here.

How were Zura Bio's earnings last quarter?

Zura Bio Limited (NASDAQ:ZURA) announced its quarterly earnings data on Tuesday, March, 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. The company had revenue of $0 million for the quarter.

How do I buy shares of Zura Bio?

Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zura Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 3/25/2025
• Today: 4/27/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZURA
• CIK: 1855644
• Web: N/A
• Phone: 858-247-0520
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.67
• High Stock Price Target: $26.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +970.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-69,240,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -37.36%
• Return on Assets: -29.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.36
• Quick Ratio: 10.36

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.85 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 68,375,000
• Free Float: 50,864,000
• Market Cap: $93.67 million
• Optionable: Optionable
• Beta: 0.08